Peginterferon for essential thrombocythemia and polycythemia vera
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a medicine called peginterferon for people with two blood disorders: essential thrombocythemia (too many platelets) and polycythemia vera (too many red blood cells). The goal is to see if peginterferon can help control these conditions and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with essential thrombocythemia or polycythemia vera according to standard medical criteria.
- You need to have a blood test and bone marrow biopsy confirming your condition.
- Your overall health should be good, with a performance status score of 0, 1, or 2.
- Your heart's pumping ability (ejection fraction) must be at least 60%.
- You must not have had peginterferon treatment before.
- You should not have other serious medical conditions like severe heart, liver, kidney, or mental health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injectable medicine (Peginterferon α-2b) for people with essential thrombocythemia (ET) whose disease is not controlled by hydroxyurea (HU) or who cannot tolerate HU. It aims to help lower high platelet counts and reduce the risk of clots or bleeding.
This study tests an injection called BEBT-507 for people with polycythemia vera (a blood condition that makes too many red blood cells). It's for those who haven't responded well to or can't tolerate standard treatments like hydroxyurea or interferon. The goal is to see if this new drug can help control the disease.
This study is testing a medicine called ropeginterferon alfa-2b for people with polycythemia vera (a blood condition) who do not have a swollen spleen that causes symptoms. It looks at how well the medicine works and how it affects your daily life through simple questionnaires.
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
This study looks at how well a drug called ropeginterferon alfa-2b works for people with polycythemia vera. It aims to understand the drug's effects and safety when used as a first or later treatment option.
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
Hear when a new Essential Thrombocythemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.